MAI Capital Management’s AbbVie ABBV Stock Holding History

MAI Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$126M	Buy	577,833 +1,766	+0.3%	+$392K	0.71%	29
2025 Q4	$132M	Buy	576,067 +29,783	+5%	+$6.78M	0.76%	27
2025 Q3	$126M	Buy	546,284 +6,850	+1%	+$1.39M	0.79%	26
2025 Q2	$100M	Buy	539,434 +19,996	+4%	+$3.72M	0.69%	31
2025 Q1	$109M	Buy	519,438 +19,745	+4%	+$3.84M	0.82%	24
2024 Q4	$88.8M	Buy	499,693 +141,380	+39%	+$26M	0.66%	33
2024 Q3	$70.8M	Sell	358,313 -14,772	-4%	-$2.76M	0.67%	36
2024 Q2	$64M	Buy	373,085 +2,235	+0.6%	+$370K	0.63%	38
2024 Q1	$67.5M	Buy	370,850 +24,229	+7%	+$4.18M	0.7%	36
2023 Q4	$53.7M	Buy	346,621 +2,218	+0.6%	+$323K	0.71%	34
2023 Q3	$51.3M	Buy	344,403 +11,807	+4%	+$1.73M	0.76%	29
2023 Q2	$44.8M	Sell	332,596 -12,686	-4%	-$1.86M	0.66%	33
2023 Q1	$55M	Sell	345,282 -1,357	-0.4%	-$207K	0.87%	27
2022 Q4	$56M	Buy	346,639 +12,629	+4%	+$1.94M	0.94%	24
2022 Q3	$44.8M	Buy	334,010 +33,749	+11%	+$4.84M	0.84%	25
2022 Q2	$46M	Buy	300,261 +1,939	+0.6%	+$296K	0.88%	26
2022 Q1	$48.4M	Buy	298,322 +4,289	+1%	+$623K	0.82%	27
2021 Q4	$39.8M	Buy	294,033 +64,837	+28%	+$7.66M	0.64%	35
2021 Q3	$24.7M	Buy	229,196 +5,196	+2%	+$594K	0.48%	54
2021 Q2	$25.2M	Sell	224,000 -20,535	-8%	-$2.31M	0.5%	48
2021 Q1	$26.5M	Sell	244,535 -55,424	-18%	-$5.93M	0.59%	43
2020 Q4	$32.1M	Buy	299,959 +13,479	+5%	+$1.3M	0.8%	29
2020 Q3	$25.1M	Sell	286,480 -61,185	-18%	-$5.76M	0.73%	35
2020 Q2	$34.1M	Buy	347,665 +261,473	+303%	+$23M	1.07%	18
2020 Q1	$6.57M	Sell	86,192 -5,601	-6%	-$477K	0.27%	82
2019 Q4	$8.13M	Buy	91,793 +30,976	+51%	+$2.57M	0.26%	91
2019 Q3	$4.61M	Buy	60,817 +524	+0.9%	+$35.9K	0.21%	109
2019 Q2	$4.38M	Sell	60,293 -93	-0.2%	-$7.31K	0.2%	114
2019 Q1	$4.87M	Buy	60,386 +330	+0.5%	+$27K	0.25%	103
2018 Q4	$5.54M	Buy	60,056 +8,561	+17%	+$753K	0.32%	88
2018 Q3	$4.87M	Sell	51,495 -526	-1%	-$49.9K	0.25%	104
2018 Q2	$4.82M	Buy	52,021 +2,533	+5%	+$247K	0.26%	102
2018 Q1	$4.68M	Buy	49,488 +4,573	+10%	+$502K	0.27%	100
2017 Q4	$4.34M	Buy	44,915 +7,048	+19%	+$664K	0.25%	104
2017 Q3	$3.37M	Buy	37,867 +2	+0%	+$152	0.2%	115
2017 Q2	$2.75M	Buy	37,865 +114	+0.3%	+$7.66K	0.18%	126
2017 Q1	$2.46M	Sell	37,751 -1,210	-3%	-$76.1K	0.17%	133
2016 Q4	$2.44M	Buy	38,961 +1,273	+3%	+$77.7K	0.18%	125
2016 Q3	$2.38M	Buy	37,688 +58	+0.2%	+$3.75K	0.18%	117
2016 Q2	$2.33M	Sell	37,630 -1,594	-4%	-$97.1K	0.18%	119
2016 Q1	$2.24M	Buy	39,224 +2,000	+5%	+$111K	0.17%	120
2015 Q4	$2.21M	Sell	37,224 -1,931	-5%	-$111K	0.17%	122
2015 Q3	$2.13M	Buy	39,155 +146	+0.4%	+$9.5K	0.16%	136
2015 Q2	$2.62M	Sell	39,009 -384	-1%	-$25.1K	0.17%	131
2015 Q1	$2.31M	Buy	39,393 +1,802	+5%	+$109K	0.15%	134
2014 Q4	$2.46M	Sell	37,591 -663	-2%	-$41.8K	0.17%	120
2014 Q3	$2.21M	Sell	38,254 -3,318	-8%	-$184K	0.21%	110
2014 Q2	$2.35M	Sell	41,572 -16,781	-29%	-$880K	0.23%	97
2014 Q1	$3M	Sell	58,353 -193,063	-77%	-$9.76M	0.3%	81
2013 Q4	$13.3M	Sell	251,416 -15,413	-6%	-$758K	1.41%	14
2013 Q3	$11.9M	Sell	266,829 -1,830	-0.7%	-$81.1K	1.55%	15
2013 Q2	$11.1M	Buy	+268,659	New	+$11.7M	1.45%	18

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MAI Capital Management's ABBV Position: Q1 2026 in Review

MAI Capital Management increased its AbbVie (ABBV) stake by 0.31% in Q1 2026, buying an estimated $392K and bringing the position to 577,833 shares worth $126M. The position accounts for 0.71% of the portfolio, ranked #29.

MAI Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $132M in Q4 2025. 4,074 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

MAI Capital Management held 577,833 shares of AbbVie worth $126M as of Q1 2026.
MAI Capital Management bought 1,766 AbbVie shares in Q1 2026, an estimated $392K.
AbbVie made up 0.71% of MAI Capital Management's portfolio in Q1 2026, its #29 holding.
MAI Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
MAI Capital Management's AbbVie position peaked at $132M in Q4 2025.
4,074 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.